Preventing infections in new multiple myeloma patients
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a drug called sulpegfilgrastim, which helps boost your body's infection-fighting white blood cells. It is given to people newly diagnosed with multiple myeloma who are starting a common treatment combination, to see if it reduces the chance of getting a serious infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and weigh more than 35 kg (about 77 pounds).
- You have been newly diagnosed with multiple myeloma and are not planning a stem cell transplant.
- Your doctor plans to treat you with a combination of drugs called DRD (daratumumab, lenalidomide, and dexamethasone) for at least 6 cycles.
- You are generally able to care for yourself (ECOG score 0-2) and expected to live at least 3 more months.
- Your blood counts are within certain limits (white blood cells and platelets not too low).
- Your kidney and liver function are adequate.
- You are not pregnant or breastfeeding, and if you can become pregnant, you agree to use effective birth control during treatment and for 1 year after.
- You have not had another cancer in the past year, are not HIV-positive, and do not have an active infection or recent antibiotic use.
- You are not allergic to the study drug or similar drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing new drugs for people recently diagnosed with multiple myeloma, a blood cancer. It aims to see if the new treatment is safe and effective, and it may offer an additional treatment option.
This trial tests a new drug called SHR-3836 for patients with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if the drug is safe and how it works against the cancer.
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
This study tests a combination of four medicines (isatuximab, bortezomib, lenalidomide, dexamethasone) for people with newly diagnosed high-risk multiple myeloma who are not having a stem cell transplant. The goal is to see if this combination can better control the disease and improve outcomes.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
This trial tests a new drug called SHR-9539 for people with multiple myeloma, a type of blood cancer. The goal is to see if it is safe and how it affects the cancer.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.